Novartis

“Novartis will pay $575 million upfront for an mRNA-encoded T-cell engager that it believes could be applied to autoimmune diseases. The agreement also includes up to $7.2 billion in earnouts.”

“Myricx Bio: UK biotech startup - Acquired by Novartis for up to $1.5B”

“Novartis will pay up to $1.5b ($1.1b upfront) to acquire Myricx Bio, a London developer of antibody-drug conjugates that had raised $114m in Series A funding.”